AB-CHMINACA

AB-CHMINACA is a synthetic cannabinoid with a lot of potential in research. This comprehensive guide will give you important information about AB – CHMINACA including its chemical properties, development, effects and recommended dosage.

Development and Background

AB-CHMINACA, a synthetic cannabinoid, was initially developed by Pfizer to be a possible analgesic. AB – CHMINACA is not approved for medical or human use. However, its unique pharmacological characteristics and structural similarity to other synthetic cannabinoids such as AB – FUBINACA and AB – PINACA have attracted considerable interest from researchers.

Chemical Name and CAS Number

The CAS number (Chemical Abstracts Service), which is used to identify the compound in scientific databases, is 1185887-13-1. The IUPAC (International Union of Pure and Applied Chemistry) name for AB-CHMINACA is N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide. This name provides researchers with a standard reference and describes the chemical structure of the compound.

Molecular Formula

The molecular formula of AB-CHMINACA is C20H28N4O2, which means that it contains 20 carbon atoms and 28 hydrogen atoms. It also contains four nitrogen atoms and two oxygen atoms. Its molecular mass is 356.46g/mol.

Shape and color of the compound

AB-CHMINACA is typically a powdery white or off-white color. Its crystalline structure makes it easy to work with and handle during research. Store AB-CHMINACA away from heat, direct sunlight, and in a dry, cool place to maintain its integrity.

Uses and effects of AB – CHMINACA

AB-CHMINACA is not approved for human consumption, nor medical use. However, it has been used in scientific research as a powerful agonist of the CB1 cannabinoid receptors. These receptors are essential in many physiological processes such as the regulation of pain, immune system function and mood regulation. Researchers are studying AB-CHMINACA in order to better understand both the endocannabinoid and synthetic cannabinoids.

AB-CHMINACA has a high affinity and selectivity towards the CB1 (brain) receptor. The compound mimics the effects of cannabinoids such as THC. These effects can include euphoria and relaxation, as well as altered perceptions and an increased appetite. Due to its potency, ABCHMINACA may also have more intense side effects.

Dosage and precautions

AB-CHMINACA, a research chemical that has not been approved by the FDA for human consumption is to be handled with extreme caution. Researchers who work with AB-CHMINACA must adhere to strict safety protocol, including wearing personal protective equipment (PPE) and implementing proper ventilation.

In vitro and in vivo, the dose of AB – CHMINACA must be determined carefully based on study objectives and conditions. When designing experiments, researchers must also consider the compound’s potency as well as its potential for adverse side effects.

AB-CHMINACA, in conclusion, is a synthetic cannabinoid of exceptional quality with significant research potential. Researchers who are interested in the endocannabinoid and synthetic cannabinoids’ potential therapeutic applications will find its unique chemical structure, pharmacological profiles, and ease of use ideal. Researchers can unlock the mysteries surrounding AB-CHMINACA by adhering to strict safety protocols, and following relevant legal guidelines.